Transcend Capital Advisors’s Bristol-Myers Squibb Company Contingent Value Rights CELG.RT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.73K | Hold |
109,175
| – | – | ﹤0.01% | 610 |
|
|
2025
Q1 | $5.46K | Sell |
109,175
-8,600
| -7% | -$430 | ﹤0.01% | 599 |
|
|
2024
Q4 | $5.77K | Hold |
117,775
| – | – | ﹤0.01% | 569 |
|
|
2024
Q3 | $5.65K | Hold |
117,775
| – | – | ﹤0.01% | 616 |
|
|
2024
Q2 | $4.83K | Hold |
117,775
| – | – | ﹤0.01% | 596 |
|
|
2024
Q1 | $6.48K | Hold |
117,775
| – | – | ﹤0.01% | 532 |
|
|
2023
Q4 | $10.6K | Hold |
117,775
| – | – | ﹤0.01% | 504 |
|
|
2023
Q3 | $11.2K | Hold |
117,775
| – | – | ﹤0.01% | 487 |
|
|
2023
Q2 | $13K | Hold |
117,775
| – | – | ﹤0.01% | 484 |
|
|
2023
Q1 | $14.1K | Hold |
117,775
| – | – | ﹤0.01% | 477 |
|
|
2022
Q4 | $13.9K | Hold |
117,775
| – | – | ﹤0.01% | 488 |
|
|
2022
Q3 | $15K | Hold |
117,775
| – | – | ﹤0.01% | 475 |
|
|
2022
Q2 | $16K | Hold |
117,775
| – | – | ﹤0.01% | 493 |
|
|
2022
Q1 | $18K | Hold |
117,775
| – | – | ﹤0.01% | 513 |
|
|
2021
Q4 | $22K | Hold |
117,775
| – | – | ﹤0.01% | 486 |
|
|
2021
Q3 | $22K | Hold |
117,775
| – | – | ﹤0.01% | 487 |
|
|
2021
Q2 | $29K | Hold |
117,775
| – | – | ﹤0.01% | 324 |
|
|
2021
Q1 | $25K | Hold |
117,775
| – | – | ﹤0.01% | 413 |
|
|
2020
Q4 | $41K | Hold |
117,775
| – | – | 0.01% | 374 |
|
|
2020
Q3 | $46K | Buy |
+117,775
| New | +$46K | 0.01% | 264 |
|
|
2020
Q2 | – | Sell |
-117,775
| Closed | -$56K | – | 132 |
|
|
2020
Q1 | $56K | Buy |
+117,775
| New | +$56K | 0.02% | 205 |
|